Comparative Pharmacology
Head-to-head clinical analysis: KIMIDESS versus LOGILIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KIMIDESS versus LOGILIA.
KIMIDESS vs LOGILIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KIMIDESS (ketoconazole) is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the cytochrome P450 enzyme lanosterol 14-alpha-demethylase.
Lorecivivt, the active component of Logilia, is a small interfering RNA (siRNA) that targets the synthesis of transthyretin (TTR) protein. It binds to a genetically conserved sequence in the 3' untranslated region of mutant and wild-type TTR mRNA, leading to its degradation via RNA interference. This reduces TTR protein production and deposition in tissues.
5 mg orally once daily, with or without food.
100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 14 hours (range 10-18 h); supports twice-daily dosing in most patients.
Terminal elimination half-life: 12–15 hours; dose adjustment recommended in renal impairment
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal elimination accounts for 50%, with the remainder undergoing metabolic clearance.
Approximately 60% renal (as unchanged drug), 40% biliary/fecal
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive